Business, energy, technology, markets and global industry news from Business News Today

EPKINLY

PharmaDeviceNews EPKINLY
A clinician reviews lymphoma treatment data as Genmab and AbbVie clarify that the Phase 3 EPCORE DLBCL-1 trial missed its sole United States overall survival endpoint despite a progression-free survival benefit for epcoritamab. Representative image.
Pharma & Biotech

Genmab and AbbVie clarify EPCORE DLBCL-1 missed sole US overall survival endpoint

Genmab and AbbVie clarify that EPCORE DLBCL-1 missed its sole US overall survival endpoint despite a PFS benefit for epcoritamab.

Read More
Representative image of an oncology infusion setting as Genmab’s epcoritamab data raises hopes for new elderly DLBCL and diffuse large B-cell lymphoma treatment options.
Pharma & Biotech

Genmab pushes epcoritamab deeper into frontline lymphoma with elderly DLBCL data

Find out how Genmab’s epcoritamab data could reshape elderly DLBCL treatment as bispecific antibodies move into frontline care.

Read More
Pharma & Biotech

Genmab ends acasunlimab trials: What it signals about bispecific immunotherapy risk

Genmab ends development of acasunlimab to focus on EPKINLY, petosemtamab, and Rina-S. Find out what this shift means for 4-1BB bispecifics today.

Read More